Kornimate/medical-research-clean huggingface dataset:
double-blind, placebo-controlled trial of eefooton in patients with chronic kidney disease

Conditions: Chronic Kidney Diseases; Renal Insufficiency, Chronic; Urologic Diseases

Summary: this phase ii study, 24-week, double-blind, study evaluated eefooton's safety and efficacy for patients with ckd stage 3 to 4 not on dialysis.

the purpose of this clinical observation and research is to evaluate the egfr changes in the renal function of patients with chronic kidney disease combination the eefooton oral solution and commonly used chemical drugs.

Eligibility criteria:
inclusion criteria: 1. patients with chronic kidney disease who have signed the subject's consent and the glomerular filtration rate (egfr) is less than 59ml/min/1.73m2 2. both male and female patients aged 20-85 years old are acceptable 3. you must be able to come back at a specific time each month during the 6-month trial exclusion criteria: 1. drug abuse. 2. heart failure (stage 3-4) 3. mental illness (psychotic disorder, epilepsy, depression, panic disorder) 4. patients who have undergone dialysis or are expected to have a kidney transplant in the last three months 5. the blood pressure still exceeds 150/90mmhg after using more than three antihypertensive drugs 6. pregnancy or planning to become pregnant or breastfeeding 7. malignant disease 8. acute illness (hepatitis, jaundice, acute myocardial infarction) in the last 3 months 9. the patient is engaged in another research study. 10. 3 months before entering the study or having used nsaids, anti-rejection drugs or performing imaging agent examinations during the study 11. you have participated in other research study in the previous month 12. you have drug dependence and drinking habits

Keywords: egfr chronic kidney diseases
peri-strips dry (psd) veritas collagen matrix staple line reinforcement for colorectal surgery

Conditions: Colorectal Cancer

Summary: purpose of the study is to assess the utility of psd veritas as a staple line reinforcement to minimize the risk of leakage during or after colo-rectal surgery.

study is designed as a prospective enrollment of patients undergoing open or laparoscopic colorectal surgery requiring the creation of an anastomosis. patients who are scheduled for elective resection of the left, anterior and low anterior colon can be enrolled in the study.

Eligibility criteria:
inclusion criteria: * patient must comply with follow-up evaluations * patient or representative must provide informed consent prior to enrollment * patient scheduled for elective surgical excision of the left, anterior or low anterior colon * patient must meet all criteria and be eligible to have open or laparoscopic colorectal surgery with primary anastomosis at one location exclusion criteria: * crohns disease * emergency colorectal surgery for trauma, obstruction, ischemic bowel, perforated diverticulum and all other emergent diagnosis. * patients who have not had mechanical bowel preparation * patients with known documented sensitivity/allergy to bovine material * severe radiation damage to tissue * carcinomatosis or stage iv cancer * bmi is 35 or greater * cancer at primary anastomosis site that cannot be excised * patients who require an ileo rectal anastomosis * surgery anticipated to include jejunostomy pouch * anticipated diverting stoma * no anti adhesive barrier can be used around anastomotic site * no multiple circular anastomosis * surgeons discretion to exclude any patient he/she feels would not have a safe anastomosis * patient life expectacny less than follow-up timeframe of study * pregnancy * patients currently enrolled in a study that competes for the same patient population

Keywords: staple line reinforcement staple line buttress anastomotic reinforcement
oral nutritional supplementation with hmb enhance muscle quality in sarcopenic surgical patients

Conditions: Sarcopenia; Frailty

Summary: aims: clinical frailty severely impacts the physical, functional and physiological reserves necessary for the recovery after surgery. sarcopenia, a multifactorial, multi-organ process which lead to loss of muscle mass over time, eventually resulting in clinical frailty. these 2 entities result in an increased morbidity and mortality from surgery. they also lead to a slower recovery from surgery with some patients never reaching baseline function after their surgery. it is, therefore, important to optimize patients with sarcopenia prior to surgery to reduce the incidence of morbidity and mortality. nutrition and resistance training have been shown to be able to curb the effects of sarcopenia. however, the type and regime of nutrition is still unknown. hypotheses: the study team hypothesize that ensure plus advance + hmb (beta-hydoxy-beta-methylbutyrate) would reduce the amount of imat (inter and intramuscular adipose tissue) in sarocpaenic patients after 2-4 weeks of prehabilitation. this effect would be sustained even after surgery and would continue to improve up to 3-months post-surgery whilst participating in rehabilitation. taking ensure plus advance + hmb would also improve functional parameters after prehabilitation, ensure a similar qol 1-month post-surgery even if biochemical parameters may not show a significant improvement. methods: the investigators would be conducting a pilot interventional cohort with an institution with an established prehabilitation programme (skh) to evaluate the effect of the use a high protein, high calorie oral nutritional supplement (ons) with hmb on muscle quality, using a device with automated intelligence (ai), in sarcopenic patients undergoing gastrointestinal surgery. primary outcomes will be changes in intermuscular adipose tissue (imat) while secondary outcomes include changes in functional parameters, quality-of-life (qol), surgical outcomes and biochemical results.


Eligibility criteria:
inclusion criteria: 1. between 40-90 years old 2. are sarcopenia (defined by the asian workgroup of sarcopenia 2019 definition) 3. due to undergo elective major gastrointestinal surgery 4. able to satisfy at least 2 weeks of prehabilitation before surgery 5. ambulant 6. able to comply with physiotherapy and dietician advice exclusion criteria: 1. are pregnant 2. are prisoners 3. intellectually, mentally or emotionally deemed not able to provide an informed consent and/or are unable to fill up the post-procedure questionnaires 4. have disease conditions requiring emergent/semi-emergent operation 5. diabetes on oral hyperglycemic agents (ohga) 6. chronic kidney disease (ckd) or end-stage renal failure (esrf) 7. unable to or decline assessment for sarcopenia

Keywords: nutrition prehabilitation surgery rehabilitation exercise hmb
frequent dosing of cera improves nutrition and inflammation in hemodialysis patients

Conditions: Anemia; Inflammation; Malnutrition

Summary: the response of continuous erythropoietic receptor activator (cera) with different dose interval and the survey for influence factors: we aim to evaluate a better clinical response which can be achieved by different dosing interval of a fixed dose of cera. we expect this study can determine the dosing schedule with better clinical response to cera and identify the associated factors predicting the cost-effectiveness of cera in maintenance hemodialysis (hd) patients in taiwan.

we included hd patients with stable hematocrit (between 30\~36%) under intravenous administration of cera 100 μg once monthly for two months. then they were shifted to receive cera 50μg twice monthly for anther two months and finally they were shifted back to receive cera 100 μg once monthly again for additional two months. then we measured and compared the erythropoietic response (hematocrit, hemoglobin), profiles of iron status as well as nutritional status and inflammatory markers among the study subjects every two months for a total of 6 months. those who had bleeding or received surgery or blood transfusion were excluded.

Eligibility criteria:
inclusion criteria: * hd patients with stable hematocrit (between 30\~36%) under intravenous administration of cera 100 μg once monthly for two months. exclusion criteria: * hd patients were excluded due to active bleeding (major trauma, gastric ulcer bleeding, or surgery), blood transfusion or administration of additional erythropoietic stimulating agent (esa) other than cera within the follow-up period during the study perod of 6 months. people who discontinued cera as their esa were also excluded.

Keywords: malnutrition, inflammation, and anemia (mia) syndrome, hemodialysis, erythropoietin stimulating agent (esa), cost-effectiveness, pharmacokinetics, endothelial dysfunction
prince22 system complete performance study

Conditions: Hearing Loss, Bilateral; Hearing Loss, Unilateral

Summary: the investigation proposes to compare a narrow reference beamformer to a novel beamformer approach, when the talker is not in front of the hearing aid user and in the presence of background noise. the beamformer effect will be determined in terms of speech intelligibility, listening effort and ability to multitask when the talkers are located on the side or in the back.


Eligibility criteria:
inclusion criteria: * experienced (minimum use duration 6 months) * adult (minimum age: 18 years) hearing aid users, * written and spoken german, * ability to understand instruction, * ability to perform tests successfully * ability to describe listening experiences, * ability to attend to the appointments, * healthy outer ear, * moderat to severe hearing * informed consent as documented by signature. exclusion criteria: * clinical contraindications deformity of the ear (closed ear canal or absence of pinna), * known hypersensitivity or allergy, * not willing to wear the hearing aid, * fluctuating hearing that could influence the results.
99mtc-anti-tnf-alpha scintigraphy in the evaluation of inflammatory processes activity

Conditions: Psoriatic Arthritis; Arthritis

Summary: rheumatoid and psoriatic arthritis patients benefit from anti-tnf-α therapy, once it is effective in reducing joint and skin manifestations in 60-70% of patients with inflammatory articular joint and skin diseases. thus, identifying the presence and amount of tnf-α in the joint or skin in these patients may help in guiding the course of treatment more efficiently. the investigators research group has developed a novel approach to label anti-tnf-α with technetium-99m. here the investigators compare the results obtained with scintigraphy and mri in rheumatoid and psoriatic arthritis. the 99mtc-anti-tnf-α scintigraphy might recognize the molecule involved in the inflammatory process and provide crucial information to help physicians taking decisions about the drugs to be used based on biological evidence and which are cost-effective and appropriate for the treatment of choice. it allows direct identification of the monoclonal antibody anti-tnf-α in the articular joints and skin while it also ensures that the drug has reached its therapeutic target. it also allows correlation between the presence of the drug and clinical responses.


Eligibility criteria:
inclusion criteria: * rheumatoid arthritis (ra) patients must have 1 joint with edema. * inflammatory lumbalgia * ankylosing spondylitis * psoriatic arthritis with active disease and skin lesion exclusion criteria: * patients that do not return to scintigraphy * pregnancy, lactation, active infection, severe concomitant disease and medication allergy history

Keywords: 99mtc-anti-tnf inflammation psoriatic arthritis rheumatoid arthritis
the impact on survival of neo-adjuvant transarterial chemoinfusion (tai) for patients with beyond milan criteria bclc stage a/b hepatocellular carcinoma who underwent hepatectomy

Conditions: Hepatocellular Carcinoma

Summary: to compare the impact on survival of neo-adjuvant tai for patients with beyond milan criteria bclc stage a/b hcc who underwent hepatectomy.


Eligibility criteria:
inclusion criteria: * older than 18 years old and younger than 75 years; * ecog ps≤1; * proven hepatocellular carcinoma according patological examination or easl/aasld diagnostic criteria; * not previous treated for tumor; * the tumor was diagnosed as bclc stage a/b and beyond milan criteria; * no distant metastasis; * the lab test could meet: * neutrophil count≥2.0×109/l; * hemoglobin≥100g/l; * platelet count≥75×109/l; * serum albumin≥35g/l; * total bilirubin\<2-times upper limit of normal; * alt\<3-times upper limit of normal; * ast\<3-times upper limit of normal; * serum creatine\<1.5-times upper limit of normal; * pt≤upper limit of normal plus 4 seconds; * inr≤2.2; * sign up consent. exclusion criteria: * cannot tolerate tai or surgery; * distant metastasis exits; * known history of other malignancy; * be allergic to related drugs; * underwent organ transplantation before; * be treated before (interferon included); * known history of hiv infection; * known history of drug or alcohol abuse; * have gi hemorrhage or cardiac/brain vascular events within 30 days; * pregnancy.
composite plug vs d-ptfe membrane in socket preservation

Conditions: Alveolar Bone Loss

Summary: the aim of the current study is to compare the effect socket sealing with flowable resin composite compared to dense polytetrafluoroethylene membrane after filling the extraction site with xenograft particles in terms of soft and hard tissue changes, procedural time, post operative pain, patients' satisfaction, and cost effectiveness.

implant placement has become the gold standard for replacing missing teeth. one of the biggest challenges present when placing implants is the lack of sufficient bone dimensions. this deficiency may be a common finding due to the process of post extraction remodeling where both bone height and width are reduced, complicating implant placement. as a result, several procedures have been suggested to address this issue. socket preservation is one of the most implemented procedures used today to limit the amount of bone lost during post extraction remodeling. the current study was designed to compare the effectiveness of using flowable composite resin for socket sealing as an alternative to using d-ptfe membranes, bypassing the added time, cost and trauma needed for tunnel preparation and membrane tucking.

Eligibility criteria:
inclusion criteria: * patients having single non-adjacent hopeless maxillary tooth in the esthetic zone that are indicated for extraction. * patients with healthy systemic condition. * patients aged from 20 to 70 years old. * good oral hygiene. * accepts 4 months follow-up period (cooperative patients). exclusion criteria: * systemic diseases or medications that might affect bone metabolism, increase surgical risk or complicate post-operative healing. * previous bone augmentation to implant site. * untreated periodontal diseases. * para-functional habits such as bruxism and clenching. * history of radiation therapy to the head and neck. * heavy smokers (≥ 10 cigarettes per day). * pregnant or lactating females. * alcoholism or drug abuse. * psychiatric problems.
safety and efficacy of adc189 in children 2-11 years old with influenza

Conditions: Influenza Type A; Influenza Type B

Summary: currently, there is only one treatment which only need one single oral dose for influenza in children five years above (baloxavir marboxil) in china. this study will test a medicine for influenza in children younger than 5 year of age to see if it is safe and effective. this is a multicenter, randomized, double-blind, controlled phase iii clinical study. the study evaluates the pharmacokinetics, safety and efficacy of adc189 tablets/granules following a single oral dose in children aged 2 to 11 years with influenza.


Eligibility criteria:
key inclusion criteria: * 1. patients aged 2 to 11 years at screening, both sex; * 2. patients were diagnosed with influenza a vairus infection/influenza b virus infection. * 3. parents willing and able to comply with study requirements, under the judgment of investigators . * 4. onset of symptoms no more than 48 hours before presentation for screening. key exclusion criteria: * 1. patients with severe influenza. * 2. pregnant or breast-feeding females * 3. patients with acute respiratory infection, tympanitis, sinusitis, or acute asthma attack within 2 weeks before screening. * 4. presence of a chronic disease or illness that may indicate increased risk for influenza-related complications. * 5. other antiviral therapy is required during screening.
effect of squalamine lactate ophthalmic solution, 0.2% in subjects with neovascular age-related macular degeneration

Conditions: Age-Related Macular Degeneration

Summary: the purpose of this study is to evaluate anatomical and functional effect of combination therapy of squalamine lactate ophthalmic solution, 0.2% administered twice daily with monthly ranibizumab intravitreal injections in patients with choroidal neovascularization due to amd.

subjects with age-related macular degeneration who meet inclusion and exclusion criteria will be randomized to receive monthly intravitreal injections of ranibizumab (lucentis®) with either squalamine lactate ophthalmic solution 0.2% or placebo eye drops twice a day for 6 months. subjects will be evaluated with clinical and imaging techniques.

Eligibility criteria:
inclusion criteria: * 50 years of age or older * a diagnosis of choroidal neovascularization secondary to age-related macular degeneration (amd) with choroidal neovascularization (cnv) comprising at least 50% of the total lesion area in the study eye * central retinal thickness ≥ 300 μm and presence of subretinal fluid or cystoid edema by optical coherence tomography (oct) * best corrected visual acuity (bcva) of 20/40 to 20/320 by early treatment diabetic retinopathy study (etdrs) protocol exclusion criteria: * neovascularization secondary to any other condition than amd in the study eye * blood occupying greater than 50% of the amd lesion, or blood \> 1.0 sq. mm underlying the fovea * ped without associated subretinal fluid and/or cystic retinal changes * clinical evidence of diabetic retinopathy or diabetic macular edema in the study eye * confounding ocular conditions in the study eye which will affect interpretation of oct, va or assessment of macular appearance (e.g., cataract, epiretinal membrane, retinal vascular occlusive disease) * fibrosis or atrophy, retinal epithelial tear in the center of the fovea in the study eye or any condition preventing va improvement * uncontrolled glaucoma in the study eye, or currently receiving topical glaucoma medication in the study eye
race-related alternative splicing: novel targets in prostate cancer

Conditions: Prostate Cancer

Summary: data from evaluating prostate cancer (pca) biopsy tissue from aa and white patients has led to the discovery of alternative splicing as a novel molecular mechanism underlying more aggressive pca in aa men. coded archival radical prostatectomy tissue specimens and annotated clinical data, questionnaire data, and ancestral genotyping data will be obtained from the racially diverse and federally funded north carolina-louisiana pca project (nc-la pcap). we will use 33 tissue specimens from each of the following 6 groups (n=198 total): white low aggressive, white intermediate aggressive, white high aggressive, aa low aggressive, aa intermediate aggressive and aa high aggressive. the aforementioned tissues will first be screened for tumor content and gleason grade by a genitourinary pathologist. to identify race-related splice variants, rna will be isolated for targeted sequencing of prioritized race-related alternatively spliced genes using the nimblegen seqcap target enrichment, seqcap rna system to capture regions of interest and the illumina hiseq sequencing platform to sequence these regions at a depth and coverage sufficient to accurately call alternative splicing events.


Eligibility criteria:
inclusion criteria: 1. confirmed diagnosis of prostate cancer. 2. self-reported race of aa or white. 3. availability of five unstained slides per radical prostatectomy specimen and an associated hematoxylin and eosin stained slide for each radical prostatectomy specimen from nc-la pcap. 4. classification of prostate cancer of low, intermediate or high aggressiveness, as defined by nc-la pcap. exclusion criteria: 1. obtained radical prostatectomy tissue is inadequate for rna analysis and/or is not positive for adenocarcinoma of the prostate of low, intermediate or high aggressiveness.
the effect of glucagon-like-peptide 1 (glp-1) receptor agonism on diabetic kidney disease

Conditions: Diabetic Kidney Disease

Summary: diabetic kidney disease (dkd) is a devastating complication of diabetes, that in it's worst form, can lead to early cardiovascular death or kidney failure. a group of medicines used to treat diabetes, glucagon-like-peptide-1 analogues (glp-1), may be able to protect people with diabetes from dkd by reducing inflammation in the kidney. this study aims to test this theory by studying the effect of glp-1 on kidney function in people with diabetes. to understand how glp-1 can affect inflammation, the investigators will give a glp-1 treatment (liraglutide) to people with dkd and monitor the effect on inflammation and kidney function using blood and urine tests. the investigators will compare these results to patients with dkd who do not receive glp-1 treatment. if glp-1 proves to be effective in reducing inflammation and improving kidney function, then it could be developed as a viable new treatment for people with dkd, and may significantly reduce the disease burden, or the risk of dkd, in people with diabetes. this would be a major advance in the treatment of dkd.

a randomised controlled trial for patients with microalbuminuria and type 2 diabetes. treatment is 0.6mg of liraglutide and is compared to standard care. treatment duration is 6 months.

Eligibility criteria:
inclusion criteria: * type 2 diabetes with a hba1c of 42-75mmol/mol (6-9%dcct) * male or female aged above 30 years * have a negative pregnancy test at screening (women of child bearing potential only) * body mass index (bmi) of 25kg/m2 or greater * on a renin-angiotensin system antagonist, at a stable dose, for at least 8 weeks before inclusion into the study * established microalbuminuria * estimated glomerular filtration rate (egfr) 30ml/min/1.73m2 or above by modification of diet in renal disease (mdrd) formula exclusion criteria: * patients with any cognitive impediment that preclude the patient from giving free and informed consent * patients on dipeptidyl peptidase 4 inhibitors or thiazolidinedione treatment * patients with stage 4-5 renal disease, defined as an egfr of 30ml/min/1.73m2 or less * patients who have used a glp-1 agent in the last 6 months * female patients of child bearing potential who are pregnant, breastfeeding, or unwilling to practice an acceptable barrier and/or hormonal method of contraception or abstinence during participation in the study * previous pancreatitis * hypersensitivity to glp-1 analogues * proliferative diabetic retinopathy * any other contraindications, as per the smpc for liraglutide * patients with any other clinical condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with the dosing requirements * concurrent treatment with an investigational drug or participation in another clinical trial * use of an investigational drug within 4 weeks or 5 half-lives, whichever is longer, preceding the first dose of investigational medicinal product

Keywords: kidney diabetes glp-1